24-hour monitoring of eye pressure using a smart contact lens
Pivotal Clinical Study to Evaluate the Smartlens miLens Measurement Performance and Safety Over a 24-hour Wear Period
This study is testing a new smart contact lens that measures eye pressure in people with glaucoma and healthy individuals to see how well it works compared to regular eye tests.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 125 (estimated) |
| Ages | 22 Years to 80 Years |
| Sex | All |
| Sponsor | Smartlens, Inc. Industry-sponsored |
| Locations | 3 sites (Fullerton, California and 2 other locations) |
| Trial ID | NCT06689696 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the performance and safety of the Smartlens miLens contact lens in monitoring intraocular pressure (IOP) in adults with glaucoma and healthy participants. Participants will wear the contact lens in one eye for up to 24 hours and capture IOP measurements using a smartphone camera every 15 minutes while awake. The study will assess the ability of the lens to detect natural variations in eye pressure and compare these readings to traditional eye pressure measurements taken in a clinical setting. Participants will also report on their comfort levels while wearing the lens.
Who should consider this trial
Good fit: Ideal candidates include adults aged 22 to 80 with a diagnosis of primary open-angle glaucoma or ocular hypertension.
Not a fit: Patients with significant structural or functional glaucomatous damage or those outside the specified age range may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a non-invasive method for continuous monitoring of eye pressure, improving glaucoma management.
How similar studies have performed: While similar approaches to IOP monitoring have been explored, the use of a smart contact lens for continuous monitoring is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
1. Subjects ≥22 to ≤80 years of age
2. Subjects with:
* prior diagnosis of POAG in at least one eye, including normal tension glaucoma or prior diagnosis of POAG suspect including OHTN in at least one eye for whom no evidence or suspicion of structural or functional glaucomatous damage exists
* Diagnosis of POAG from medical records characterized by open angles and (1) optic nerve cupping consistent with glaucoma, with diffuse or focal thinning of neuroretinal rim or nerve fiber layer defects or a difference in cup/disc ratio \> 0.2, not explained by anisometropia or other non-glaucomatous causes (2) visual field defects consistent with optic nerve cupping, with glaucomatous hemifield test outside normal limits or a pattern standard deviation (PSD) worse than 5th percentile (P\<0.05) by Standard Automated Perimetry, or VF defects with Goldmann visual field test consistent with glaucomatous nerve fiber layer loss including paracentral scotoma, nasal step or arcuate defects
* Diagnosis of POAG suspect from medical records established by open angles and IOP ≥22 mmHg (OHTN) OR abnormal appearing optic disc appearance OR glaucomatous visual field defects
* no prior history of POAG/OHTN in either eye
3. In subjects with no history of POAG/OHTN, GAT IOP difference between eyes must be ≤ 2 mmHg, with IOP no less than 10 mmHg in both eyes and no greater than 21 mmHg in both eyes.
4. Mean keratometry value is between 7.5 mm and 8.2 mm in at least one eye (the miLens eye)
5. GEN4 miLens contact lens fitting on the subject's eye is acceptable by a slit lamp exam at Day 0 (measurement study visit)
6. Subjects with ability to discontinue habitual IOP-lowering medications, if any, in both eyes on Day 0 visit until the end of the 24-hour wear period (and if applicable, similarly for the Week 1 visit) (No preservative-free topical glaucoma medications will be allowed for the duration of the study)
7. Able to understand, sign and complete the informed consent and available to complete the minimum set of self-acquired smartphone images over the 24-hour contact lens wear period, preferably at an assigned site and likely available for a repeat session after a week
Exclusion Criteria:
1. BCVA worse than 20/200 in either eye
2. Greater than 6 diopters spherical equivalent in either eye
3. Greater than 3 diopters of keratometric cylinder in either eye
4. Central corneal thickness greater than 0.60 mm or less than 0.50 mm in either eye (per GAT study guidelines in ANSI Z80.10)
5. Known history of difficulty in obtaining Goldmann IOP measurements or any factors that might contribute to inaccurate Goldmann IOP measurements (e.g. lid squeezing or tremor)
6. Subjects who have had ocular surgery within the last 6 months in either eye
7. Subjects who have had corneal refractive surgery
8. History of Keratoconus, corneal scarring, or other chronic corneal disease in either eye
9. Subjects with contraindication for wearing contact lenses or history of intolerance or difficulties associated with contact lens use including history of dry eye disease
10. Subjects with current signs/symptoms of clinically significant dry eye disease
11. Active eye disease, injury or ocular abnormalities affecting the cornea, conjunctiva, or eyelids or slit lamp findings ≥ grade 3
12. Active inflammation of either eye
13. Active infection of either eye
14. Corneal vascularization of either eye
15. Known allergy to silicone
16. Known allergy to corneal anesthetic
17. Secondary forms of open angle glaucoma (OAG) in either eye
18. Poor or eccentric fixation in either eye
19. Nystagmus
20. Microphthalmos of either eye
21. Buphthalmos of either eye
22. Subject is pregnant, lactating or planning to become pregnant during the course of the study
23. Concurrent participation in any clinical trial
24. Disabling arthritis or limited motor coordination that might limit self-handling of a smart phone with miLens eyepiece attached.
25. Experience using or interacting with miLens and smartphone imaging app during a previous usability or clinical trial
26. Any affiliation with Smartlens and its employees
27. Subjects with any significant dermatologic condition (e.g., history of skin irritation, allergies, skin eczema) that poses a concern for skin contact with the camera eyepiece, based on the Investigator's judgment
Where this trial is running
Fullerton, California and 2 other locations
- Nvision Clinical Reseacrh, LLC — Fullerton, California, United States (Recruiting)
- North Bay Eye Associates, Inc. — Petaluma, California, United States (Recruiting)
- Nvision Clinical Research, LLC — Torrance, California, United States (Recruiting)
Study contacts
- Study coordinator: Chief Medical Officer
- Email: clinical@smartlens.health
- Phone: 650-288-4485
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.